Research advances in the association between microcirculation disturbance and microvascular system in metabolic associated fatty liver disease

Anqi LI; Yuqiang ZHAO; Peiran ZHAO; Rui WANG; Jing YANG

doi:10.3969/j.issn.1001-5256.2023.08.026

Volume 39 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(8): 1939-1945

PDF( 1692 KB)

Research advances in the association between microcirculation disturbance and microvascular system in metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.08.026

College of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin 150040, China

Research funding:

Heilongjiang Province Excellent Young Talents Program (2020YQ05)

More Information

Corresponding author: YANG Jing, yangjingdx@sina.com (ORCID: 0000-0003-4770-3515)
Received Date: 2023-02-13
Accepted Date: 2023-03-30
Published Date: 2023-08-20

Abstract

Abstract

Metabolic associated fatty liver disease (MAFLD) is considered a multisystem disease that can lead to multiple extrahepatic complications, among which cardiovascular disease (CVD) is the most common cause of death in MAFLD patients. MAFLD and its complications share many common metabolic risk factors, which increase the susceptibility to diabetes, hypertension, atherosclerosis, and venous thrombosis through the mechanisms such as inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and abnormal lipid metabolism, and there is a complex interaction between such factors and the pathology of MAFLD, thereby promoting the occurrence of each other. During the progression of MAFLD, there might be changes in various parts of the liver microvasculature, resulting in hepatic microcirculation disturbance, and intrahepatic microvascular disturbance and microcirculation dysfunction are the key to the progression of extrahepatic complications, but MAFLD has not yet been taken seriously like other traditional risk factors. An in-depth understanding of the association between pathological changes of the microvasculature and microcirculation disturbance in MAFLD will help with the mechanism research and treatment of the extrahepatic complications of MAFLD, and more importantly, help MAFLD patients pay more attention to healthcare outside the liver.
- Metabolic Associated Fatty Liver Disease,
- Microvessels,
- Microcirculation

FullText(HTML)

References(52)

References

[1]	BOECKMANS J, ROMBAUT M, DEMUYSER T, et al. Infections at the nexus of metabolic-associated fatty liver disease[J]. Arch Toxicol, 2021, 95(7): 2235-2253. DOI: 10.1007/s00204-021-03069-1.
[2]	SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156.
[3]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
[4]	CHEN L, WU N, KENNEDY L, et al. Inhibition of secretin/secretin receptor axis ameliorates NAFLD phenotypes[J]. Hepatology, 2021, 74(4): 1845-1863. DOI: 10.1002/hep.31871.
[5]	TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56(11): 951-963. DOI: 10.1007/s00535-021-01796-x.
[6]	BYRNE CD, TARGHER G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64. DOI: 10.1016/j.jhep.2014.12.012.
[7]	LOOMBA R, FRIEDMAN SL, SHULMAN GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564. DOI: 10.1016/j.cell.2021.04.015.
[8]	XU M, XU HH, LIN Y, et al. LECT2, a ligand for tie1, plays a crucial role in liver fibrogenesis[J]. Cell, 2019, 178(6): 1478-1492. e20. DOI: 10.1016/j.cell.2019.07.021.
[9]	CATALDO I, SARCOGNATO S, SACCHI D, et al. Pathology of non-alcoholic fatty liver disease[J]. Pathologica, 2021, 113(3): 194-202. DOI: 10.32074/1591-951X-242.
[10]	BASSEGODA O, OLIVAS P, TURCO L, et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2276-2286. e6. DOI: 10.1016/j.cgh.2021.10.023.
[11]	ZHOU R, FAN X, SCHNABL B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies[J]. Transl Res, 2019, 209: 22-38. DOI: 10.1016/j.trsl.2019.02.005.
[12]	KÖNIGSHOFER P, HOFER BS, BRUSILOVSKAYA K, et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies[J]. Hepatology, 2022, 75(3): 610-622. DOI: 10.1002/hep.32220.
[13]	van der GRAAFF D, CHOTKOE S, DE WINTER B, et al. Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD[J]. JHEP Rep, 2022, 4(2): 100412. DOI: 10.1016/j.jhepr.2021.100412.
[14]	ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[15]	BAFFY G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int, 2019, 39(4): 598-609. DOI: 10.1111/liv.13986.
[16]	RODRIGUES SG, MONTANI M, GUIXÉ-MUNTET S, et al. Patients with signs of advanced liver disease and clinically significant portal hypertension do not necessarily have cirrhosis[J]. Clin Gastroenterol Hepatol, 2019, 17(10): 2101-2109. e1. DOI: 10.1016/j.cgh.2018.12.038.
[17]	GARCÍA-LEZANA T, RAURELL I, BRAVO M, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J]. Hepatology, 2018, 67(4): 1485-1498. DOI: 10.1002/hep.29646.
[18]	KANG N. Mechanotransduction in liver diseases[J]. Semin Liver Dis, 2020, 40(1): 84-90. DOI: 10.1055/s-0039-3399502.
[19]	CHIN L, THEISE ND, LONEKER AE, et al. Lipid droplets disrupt mechanosensing in human hepatocytes[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(1): G11-G22. DOI: 10.1152/ajpgi.00098.2020.
[20]	HO CM, HO SL, JENG YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease[J]. J Inflamm (Lond), 2019, 16: 7. DOI: 10.1186/s12950-019-0211-5.
[21]	STINE JG, NICCUM BA, ZIMMET AN, et al. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis[J]. Clin Transl Gastroenterol, 2018, 9(3): 140. DOI: 10.1038/s41424-018-0002-y.
[22]	GABALLA D, BEZINOVER D, KADRY Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index[J]. Liver Transpl, 2019, 25(12): 1747-1755. DOI: 10.1002/lt.25630.
[23]	ABDEL-RAZIK A, MOUSA N, SHABANA W, et al. De novo portal vein thrombosis in non-cirrhotic non-alcoholic fatty liver disease: a 9-year prospective cohort study[J]. Front Med (Lausanne), 2021, 8: 650818. DOI: 10.3389/fmed.2021.650818.
[24]	de GOTTARDI A, RAUTOU P E, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[25]	de GOTTARDI A, SEMPOUX C, BERZIGOTTI A. Porto-sinusoidal vascular disorder[J]. J Hepatol, 2022, 77(4): 1124-1135. DOI: 10.1016/j.jhep.2022.05.033.
[26]	BALAKRISHNAN M, GARCIA-TSAO G, DENG Y, et al. Hepatic arteriolosclerosis: a small-vessel complication of diabetes and hypertension[J]. Am J Surg Pathol, 2015, 39(7): 1000-1009. DOI: 10.1097/PAS.0000000000000419.
[27]	PANDAY R, MONCKTON CP, KHETANI SR. The role of liver zonation in physiology, regeneration, and disease[J]. Semin Liver Dis, 2022, 42(1): 1-16. DOI: 10.1055/s-0041-1742279.
[28]	LI J, ZHANG X, TIAN J, et al. CX08005, a protein tyrosine phosphatase 1b inhibitor, attenuated hepatic lipid accumulation and microcirculation dysfunction associated with nonalcoholic fatty liver disease[J]. Pharmaceuticals (Basel), 2023, 16(1): 106. DOI: 10.3390/ph16010106.
[29]	WISSE E, BRAET F, SHAMI GJ, et al. Fat causes necrosis and inflammation in parenchymal cells in human steatotic liver[J]. Histochem Cell Biol, 2022, 157(1): 27-38. DOI: 10.1007/s00418-021-02030-8.
[30]	MATHIEU M, MARTIN-JAULAR L, LAVIEU G, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J]. Nat Cell Biol, 2019, 21(1): 9-17. DOI: 10.1038/s41556-018-0250-9.
[31]	HERNÁNDEZ A, ARAB JP, REYES D, et al. Extracellular vesicles in NAFLD/ALD: from pathobiology to therapy[J]. Cells, 2020, 9(4): 817. DOI: 10.3390/cells9040817.
[32]	JIANG F, CHEN Q, WANG W, et al. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1[J]. J Hepatol, 2020, 72(1): 156-166. DOI: 10.1016/j.jhep.2019.09.014.
[33]	LIU XL, PAN Q, CAO HX, et al. Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through Rictor/Akt/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 72(2): 454-469. DOI: 10.1002/hep.31050.
[34]	XU M, XU H H, LIN Y, et al. LECT2, a Ligand for tie1, plays a crucial role in liver fibrogenesis[J]. Cell, 2019, 178(6): 1478-1492. e20. DOI: 10.1016/j.cell.2019.07.021.
[35]	YE L, CAO Z, LAI X, et al. Niacin Ameliorates hepatic steatosis by inhibiting De Novo lipogenesis via a GPR109A-Mediated PKC-ERK1/2-AMPK signaling pathway in C57BL/6 mice fed a high-fat diet[J]. J Nutr, 2020, 150(4): 672-684. DOI: 10.1093/jn/nxz303.
[36]	BARROW F, KHAN S, WANG H, et al. The emerging role of B cells in the pathogenesis of NAFLD[J]. Hepatology, 2021, 74(4): 2277-2286. DOI: 10.1002/hep.31889.
[37]	OGRESTA D, MRZLJAK A, CIGROVSKI BERKOVIC M, et al. Coagulation and endothelial dysfunction associated with NAFLD: current status and therapeutic implications[J]. J Clin Transl Hepatol, 2022, 10(2): 339-355. DOI: 10.14218/JCTH.2021.00268.
[38]	BRESLIN JW, YANG Y, SCALLAN JP, et al. Lymphatic vessel network structure and physiology[J]. Compr Physiol, 2018, 9(1): 207-299. DOI: 10.1002/cphy.c180015.
[39]	TAMBURINI B, FINLON JM, GILLEN AE, et al. Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells[J]. Front Immunol, 2019, 10: 1036. DOI: 10.3389/fimmu.2019.01036.
[40]	BURCHILL MA, FINLON JM, GOLDBERG AR, et al. Oxidized low-density lipoprotein drives dysfunction of the liver lymphatic system[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2): 573-595. DOI: 10.1016/j.jcmgh.2020.09.007.
[41]	DUONG CN, VESTWEBER D. Mechanisms ensuring endothelial junction integrity beyond VE-cadherin[J]. Front Physiol, 2020, 11: 519. DOI: 10.3389/fphys.2020.00519.
[42]	TAMBURINI B, FINLON JM, GILLEN AE, et al. Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells[J]. Front Immunol, 2019, 10: 1036. DOI: 10.3389/fimmu.2019.01036.
[43]	BURCHILL MA, FINLON JM, GOLDBERG AR, et al. Oxidized low-density lipoprotein drives dysfunction of the liver lymphatic system[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2): 573-595. DOI: 10.1016/j.jcmgh.2020.09.007.
[44]	SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68(2): 238-250. DOI: 10.1016/j.jhep.2017.11.012.
[45]	YILDIZ E, EL ALAM G, PERINO A, et al. Hepatic lipid overload triggers biliary epithelial cell activation via E2Fs[J]. Elife, 2023. DOI: 10.7554/eLife.81926.
[46]	YANG P, WANG Y, TANG W, et al. Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice[J]. Sci Rep, 2020, 10(1): 4701. DOI: 10.1038/s41598-020-61473-6.
[47]	CLOUGH GF, CHIPPERFIELD AJ, THANAJ M, et al. Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis[J]. Front Physiol, 2020, 11: 551. DOI: 10.3389/fphys.2020.00551.
[48]	ADORI C, DARAIO T, KUIPER R, et al. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging[J]. Sci Adv, 2021, 7(30): eabg5733. DOI: 10.1126/sciadv.abg5733.
[49]	HURR C, SIMONYAN H, MORGAN DA, et al. Liver sympathetic denervation reverses obesity-induced hepatic steatosis[J]. J Physiol, 2019, 597(17): 4565-4580. DOI: 10.1113/JP277994.
[50]	CLOUGH GF, CHIPPERFIELD AJ, THANAJ M, et al. Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis[J]. Front Physiol, 2020, 11: 551. DOI: 10.3389/fphys.2020.00551.
[51]	PRANDONI P. Is there a link between venous and arterial thrombosis? A reappraisal[J]. Intern Emerg Med, 2020, 15(1): 33-36. DOI: 10.1007/s11739-019-02238-6.
[52]	ZUO R, YE LF, HUANG Y, et al. Hepatic small extracellular vesicles promote microvascular endothelial hyperpermeability during NAFLD via novel-miRNA-7[J]. J Nanobiotechnology, 2021, 19(1): 396. DOI: 10.1186/s12951-021-01137-3.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (297) PDF downloads(52)

Research advances in the association between microcirculation disturbance and microvascular system in metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.08.026

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in the association between microcirculation disturbance and microvascular system in metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.08.026

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content